Pfizer shares fell as much as 5% Tuesday morning on what some market watchers called underwhelming study results for an experimental weight-loss drug the drugmaker obtained after a contentious and ...

Pfizer has fallen behind the pack when it comes to GLP-1 drugs, but the company is still fighting.

Pfizer reported a quarterly loss Tuesday following a large write-down, denting shares as it confirmed 2026 financial targets with lower revenues. "Current financial guidance does not anticipate any ...

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...